{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T12:26:06Z","timestamp":1759580766429},"reference-count":111,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2002,9,1]],"date-time":"2002-09-01T00:00:00Z","timestamp":1030838400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Lymphoma"],"published-print":{"date-parts":[[2002,9]]},"DOI":"10.3816\/clm.2002.n.014","type":"journal-article","created":{"date-parts":[[2008,9,11]],"date-time":"2008-09-11T01:09:54Z","timestamp":1221095394000},"page":"90-96","source":"Crossref","is-referenced-by-count":6,"title":["Mantle Cell Lymphoma: New Treatments Targeted to the Biology"],"prefix":"10.3816","volume":"3","author":[{"given":"Francesco","family":"Bertoni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Ghielmini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franco","family":"Cavalli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Finbarr E.","family":"Cotter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emanuele","family":"Zucca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.3816\/CLM.2002.n.014_bib1","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1182\/blood.V89.11.3909","article-title":"A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma","volume":"89","author":"The Non-Hodgkin's Lymphoma Classification Project","year":"1997","journal-title":"Blood"},{"key":"10.3816\/CLM.2002.n.014_bib2","series-title":"Malignant Lymphoma","first-page":"27","article-title":"Mantle cell lymphoma","author":"Weisenburger","year":"2000"},{"key":"10.3816\/CLM.2002.n.014_bib3","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1093\/oxfordjournals.annonc.a058904","article-title":"European Lymphoma Task Force (ELTF): Report of the workshop on Mantle Cell Lymphoma (MCL)","volume":"5","author":"Zucca","year":"1994","journal-title":"Ann Oncol"},{"key":"10.3816\/CLM.2002.n.014_bib4","first-page":"115","article-title":"Mantle-cell lymphoma","volume":"36","author":"Campo","year":"1999","journal-title":"Semin Hematol"},{"key":"10.3816\/CLM.2002.n.014_bib5","doi-asserted-by":"crossref","first-page":"197","DOI":"10.3816\/CLM.2000.n.016","article-title":"Pathologic diagnosis of mantle cell lymphoma","volume":"1","author":"Lai","year":"2000","journal-title":"Clin Lymphoma"},{"key":"10.3816\/CLM.2002.n.014_bib6","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1182\/blood.V84.5.1361.1361","article-title":"A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group","volume":"84","author":"Harris","year":"1994","journal-title":"Blood"},{"key":"10.3816\/CLM.2002.n.014_bib7","series-title":"Annual of Lymphoid Malignancies","first-page":"61","article-title":"Mantle cell lymphoma","author":"Dreyling","year":"2001"},{"key":"10.3816\/CLM.2002.n.014_bib8","series-title":"World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues","first-page":"168","article-title":"Mantle cell lymphoma","author":"Swerdlow","year":"2001"},{"key":"10.3816\/CLM.2002.n.014_bib9","first-page":"1308","article-title":"The pathologist's view point. Part II \u2013 aggressive lymphomas","volume":"85","author":"Pileri","year":"2000","journal-title":"Haematologica"},{"key":"10.3816\/CLM.2002.n.014_bib10","first-page":"198","article-title":"Indolent nonfollicular lymphomas: characteristics, treatment, and outcome","volume":"36","author":"Coiffier","year":"1999","journal-title":"Semin Hematol"},{"key":"10.3816\/CLM.2002.n.014_bib11","first-page":"325","article-title":"Mantle cell lymphoma: prognostic factors and treatment results","author":"Fisher","year":"1999","journal-title":"Hematology. American Society of Hematology Education Program Book"},{"key":"10.3816\/CLM.2002.n.014_bib12","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1200\/JCO.1998.16.1.3","article-title":"Which treatment for mantle-cell lymphoma patients in 1998?","volume":"16","author":"Coiffier","year":"1998","journal-title":"J Clin Oncol"},{"issue":"suppl 2","key":"10.3816\/CLM.2002.n.014_bib13","first-page":"S60","article-title":"Mantle cell lymphoma: diagnostic criteria, clinical aspects and therapeutic problems","volume":"11","author":"Meusers","year":"1997","journal-title":"Leukemia"},{"key":"10.3816\/CLM.2002.n.014_bib14","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1002\/(SICI)1097-0142(19980201)82:3<567::AID-CNCR20>3.0.CO;2-Z","article-title":"Mantle cell lymphoma: presenting features, response to therapy, and prognostic factors","volume":"82","author":"Bosch","year":"1998","journal-title":"Cancer"},{"key":"10.3816\/CLM.2002.n.014_bib15","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S0959-8049(97)10056-9","article-title":"Mantle cell lymphoma: clinical features, treatment and prognosis of 94 patients","volume":"34","author":"Oinonen","year":"1998","journal-title":"Eur J Cancer"},{"key":"10.3816\/CLM.2002.n.014_bib16","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1038\/sj.leu.2401121","article-title":"Mantle cell lymphoma: a retrospective study of 121 cases","volume":"12","author":"Samaha","year":"1998","journal-title":"Leukemia"},{"key":"10.3816\/CLM.2002.n.014_bib17","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/oxfordjournals.annonc.a059155","article-title":"Patterns of survival in mantle cell lymphoma","volume":"6","author":"Zucca","year":"1995","journal-title":"Ann Oncol"},{"key":"10.3816\/CLM.2002.n.014_bib18","first-page":"329","article-title":"Mantle cell lymphoma: new treatment possibilities","author":"Coiffier","year":"1999","journal-title":"Hematology. American Society of Hematology Education Program Book"},{"key":"10.3816\/CLM.2002.n.014_bib19","series-title":"American Society of Clinical Oncology Educational Book","first-page":"416","article-title":"Management of mantle cell lymphoma","author":"Cabanillas","year":"2002"},{"key":"10.3816\/CLM.2002.n.014_bib20","doi-asserted-by":"crossref","first-page":"4212","DOI":"10.1182\/blood.V90.10.4212","article-title":"Failure of immunologic purging in mantle cell lymphoma assessed by polymerase chain reaction detection of minimal residual disease","volume":"90","author":"Andersen","year":"1997","journal-title":"Blood"},{"issue":"suppl 1","key":"10.3816\/CLM.2002.n.014_bib21","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1093\/annonc\/8.suppl_1.S103","article-title":"Treatment of mantle-cell lymphomas with the VAD +\/- chlorambucil regimen with or without subsequent high-dose therapy and peripheral blood stem-cell transplantation","volume":"8","author":"Gressin","year":"1997","journal-title":"Ann Oncol"},{"key":"10.3816\/CLM.2002.n.014_bib22","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1023\/A:1008278605751","article-title":"Intensive therapy with peripheral stem cell transplantation in 16 patients with mantle cell lymphoma","volume":"8","author":"Ketterer","year":"1997","journal-title":"Ann Oncol"},{"key":"10.3816\/CLM.2002.n.014_bib23","first-page":"1975","article-title":"Myeloablative therapy with blood stem cell transplantation is effective in mantle cell lymphoma","volume":"10","author":"Haas","year":"1996","journal-title":"Leukemia"},{"key":"10.3816\/CLM.2002.n.014_bib24","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1182\/blood.V89.2.724","article-title":"Molecular monitoring of minimal residual disease in follicular and mantle cell non-Hodgkin's lymphomas treated with high-dose chemotherapy and peripheral blood progenitor cell autografting","volume":"89","author":"Corradini","year":"1997","journal-title":"Blood"},{"key":"10.3816\/CLM.2002.n.014_bib25","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1023\/A:1008251301319","article-title":"Sequential high-dose therapy and autologous stem cell transplantation for treatment of mantle cell lymphoma","volume":"8","author":"Dreger","year":"1997","journal-title":"Ann Oncol"},{"key":"10.3816\/CLM.2002.n.014_bib26","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/sj.bmt.1701033","article-title":"Long-term disease-free survival of patients with advanced mantle-cell lymphoma following high-dose chemotherapy","volume":"21","author":"Kroger","year":"1998","journal-title":"Bone Marrow Transplant"},{"key":"10.3816\/CLM.2002.n.014_bib27","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/sj.leu.2402406","article-title":"Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma: a prospective study","volume":"16","author":"Lefrere","year":"2002","journal-title":"Leukemia"},{"key":"10.3816\/CLM.2002.n.014_bib28","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1038\/sj.bmt.1703255","article-title":"Stem cell transplantation for mantle cell lymphoma: should it ever be used outside clinical trials?","volume":"28","author":"Sweetenham","year":"2001","journal-title":"Bone Marrow Transplant"},{"key":"10.3816\/CLM.2002.n.014_bib29","series-title":"American Society of Clinical Oncology Educational Book","first-page":"407","article-title":"Treatment of mantle-cell lymphoma: stem-cell transplantation, radioimmunotherapy, and management of mantle-cell lymphoma subsets","author":"Press","year":"2002"},{"key":"10.3816\/CLM.2002.n.014_bib30","first-page":"482a","article-title":"Does transplantation improve outcome in mantle cell lymphoma (MCL)?: a study from the EBMT","volume":"96","author":"Vandenberghe","year":"2000","journal-title":"Blood"},{"key":"10.3816\/CLM.2002.n.014_bib31","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1182\/blood.V96.3.864","article-title":"Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion","volume":"96","author":"Magni","year":"2000","journal-title":"Blood"},{"key":"10.3816\/CLM.2002.n.014_bib32","doi-asserted-by":"crossref","first-page":"3803","DOI":"10.1200\/JCO.1998.16.12.3803","article-title":"Hyper-CVAD and high-dose methotrexate\/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma","volume":"16","author":"Khouri","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2002.n.014_bib33","first-page":"66","article-title":"Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma","volume":"26","author":"Grillo-Lopez","year":"1999","journal-title":"Semin Oncol"},{"key":"10.3816\/CLM.2002.n.014_bib34","first-page":"74","article-title":"Preclinical and phase I and II trials of rituximab","volume":"26","author":"Maloney","year":"1999","journal-title":"Semin Oncol"},{"key":"10.3816\/CLM.2002.n.014_bib35","first-page":"79","article-title":"Rituximab in indolent lymphoma: the single-agent pivotal trial","volume":"26","author":"McLaughlin","year":"1999","journal-title":"Semin Oncol"},{"key":"10.3816\/CLM.2002.n.014_bib36","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1083\/jcb.121.5.1121","article-title":"Transfection of the CD20 cell surface molecule into ectopic cell types generates a Ca2+ conductance found constitutively in B lymphocytes","volume":"121","author":"Bubien","year":"1993","journal-title":"J Cell Biol"},{"key":"10.3816\/CLM.2002.n.014_bib37","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1006\/bcmd.2000.0287","article-title":"Clustered CD20 induced apoptosis: src-family kinase, the proximal regulator of tyrosine phosphorylation, calcium influx, and caspase 3-dependent apoptosis","volume":"26","author":"Hofmeister","year":"2000","journal-title":"Blood Cells Mol Dis"},{"key":"10.3816\/CLM.2002.n.014_bib38","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s002620050016","article-title":"Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells","volume":"48","author":"Shan","year":"2000","journal-title":"Cancer Immunol Immunother"},{"key":"10.3816\/CLM.2002.n.014_bib39","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1182\/blood.V99.3.1038","article-title":"The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction","volume":"99","author":"Byrd","year":"2002","journal-title":"Blood"},{"key":"10.3816\/CLM.2002.n.014_bib40","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1182\/blood.V97.5.1392","article-title":"Homodimers but not monomers of Rituxan (chimeric anti-CD20) induce apoptosis in human B-lymphoma cells and synergize with a chemotherapeutic agent and an immunotoxin","volume":"97","author":"Ghetie","year":"2001","journal-title":"Blood"},{"key":"10.3816\/CLM.2002.n.014_bib41","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1006\/cimm.2000.1693","article-title":"Mechanism of cytotoxicity induced by chimeric mouse human monoclonal antibody IDEC-C2B8 in CD20-expressing lymphoma cell lines","volume":"204","author":"Flieger","year":"2000","journal-title":"Cell Immunol"},{"key":"10.3816\/CLM.2002.n.014_bib42","doi-asserted-by":"crossref","first-page":"3900","DOI":"10.1182\/blood.V95.12.3900","article-title":"Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis","volume":"95","author":"Golay","year":"2000","journal-title":"Blood"},{"key":"10.3816\/CLM.2002.n.014_bib43","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1182\/blood.V91.5.1644","article-title":"Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies","volume":"91","author":"Shan","year":"1998","journal-title":"Blood"},{"key":"10.3816\/CLM.2002.n.014_bib44","first-page":"33","article-title":"Anti-CD20 antibody (IDEC C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases","volume":"87","author":"Chow","year":"2002","journal-title":"Haematologica"},{"key":"10.3816\/CLM.2002.n.014_bib45","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1046\/j.1365-3083.2000.00745.x","article-title":"Rituximab (anti-CD20) therapy of Bcell lymphomas: direct complement killing is superior to cellular effector mechanisms","volume":"51","author":"Harjunpaa","year":"2000","journal-title":"Scand J Immunol"},{"key":"10.3816\/CLM.2002.n.014_bib46","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.1182\/blood.V98.9.2771","article-title":"Complement-mediated cell death induced by rituximab in B-cell lymphoproliferative disorders is mediated in vitro by a caspase-independent mechanism involving the generation of reactive oxygen species","volume":"98","author":"Bellosillo","year":"2001","journal-title":"Blood"},{"key":"10.3816\/CLM.2002.n.014_bib47","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1097\/00002371-200105000-00011","article-title":"Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies","volume":"24","author":"Treon","year":"2001","journal-title":"J Immunother"},{"key":"10.3816\/CLM.2002.n.014_bib48","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1182\/blood.V98.5.1352","article-title":"Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma","volume":"98","author":"Weng","year":"2001","journal-title":"Blood"},{"key":"10.3816\/CLM.2002.n.014_bib49","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1046\/j.1365-2141.2000.02271.x","article-title":"Controlling the mitochondrial gatekeeper for effective chemotherapy","volume":"111","author":"Fennell","year":"2000","journal-title":"Br J Haematol"},{"key":"10.3816\/CLM.2002.n.014_bib50","first-page":"709","article-title":"Inhibition of interleukin 10 by rituximab results in down-regulation of bcl-2 and sensitization of B-cell non- Hodgkin's lymphoma to apoptosis","volume":"7","author":"Alas","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CLM.2002.n.014_bib51","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1038\/sj.leu.2401829","article-title":"Mantle cell lymphoma proliferates upon IL-10 in the CD40 system","volume":"14","author":"Visser","year":"2000","journal-title":"Leukemia"},{"key":"10.3816\/CLM.2002.n.014_bib52","first-page":"1927","article-title":"Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study","volume":"92","author":"Coiffier","year":"1998","journal-title":"Blood"},{"key":"10.3816\/CLM.2002.n.014_bib53","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1200\/JCO.2000.18.2.317","article-title":"European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantlecell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma","volume":"18","author":"Foran","year":"2000","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"10.3816\/CLM.2002.n.014_bib54","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1093\/annonc\/11.suppl_1.S117","article-title":"Treatment of mantle-cell lymphoma with rituximab (chimeric monoclonal anti-CD20 antibody): analysis of factors associated with response","volume":"11","author":"Foran","year":"2000","journal-title":"Ann Oncol"},{"key":"10.3816\/CLM.2002.n.014_bib55","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1600-0609.1999.tb01725.x","article-title":"IDEC-C2B8 anti-CD20 (rituximab) immunotherapy in patients with low-grade non-Hodgkin's lymphoma and lymphoproliferative disorders: evaluation of response on 48 patients","volume":"62","author":"Nguyen","year":"1999","journal-title":"Eur J Haematol"},{"issue":"suppl 1","key":"10.3816\/CLM.2002.n.014_bib56","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1093\/annonc\/11.suppl_1.S123","article-title":"The effect of rituximab on patients with follicular and mantle-cell lymphoma. Swiss Group for Clinical Cancer Research (SAKK)","volume":"11","author":"Ghielmini","year":"2000","journal-title":"Ann Oncol"},{"key":"10.3816\/CLM.2002.n.014_bib57","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1089\/cbr.1997.12.177","article-title":"Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs","volume":"12","author":"Demidem","year":"1997","journal-title":"Cancer Biother Radiopharm"},{"key":"10.3816\/CLM.2002.n.014_bib58","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1002\/(SICI)1097-0215(20000101)85:1<104::AID-IJC19>3.0.CO;2-G","article-title":"Synergistic cytotoxicity of iodine-131-anti-CD20 monoclonal antibodies and chemotherapy for treatment of B-cell lymphomas","volume":"85","author":"Johnson","year":"2000","journal-title":"Int J Cancer"},{"key":"10.3816\/CLM.2002.n.014_bib59","first-page":"2961","article-title":"Potentiation of fludarabine cytotoxicity on non-Hodgkin's lymphoma by pentoxifylline and rituximab","volume":"20","author":"Alas","year":"2000","journal-title":"Anticancer Res"},{"key":"10.3816\/CLM.2002.n.014_bib60","first-page":"808a","article-title":"Bcl-2 antisense (Genasense\u2122) induces apoptosis and potentiates activity of both cytotoxic chemotherapy and rituximab in primary CLL cells","volume":"98","author":"Auer","year":"2001","journal-title":"Blood"},{"key":"10.3816\/CLM.2002.n.014_bib61","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1200\/JCO.2001.19.2.389","article-title":"Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma","volume":"19","author":"Vose","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2002.n.014_bib62","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1023\/A:1008395214584","article-title":"Clearing of cells bearing the bcl-2 [t(14;18)] translocation from blood and marrow of patients treated with rituximab alone or in combination with CHOP chemotherapy","volume":"12","author":"Czuczman","year":"2001","journal-title":"Ann Oncol"},{"key":"10.3816\/CLM.2002.n.014_bib63","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N Engl J Med"},{"key":"10.3816\/CLM.2002.n.014_bib64","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1200\/JCO.20.5.1288","article-title":"Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival","volume":"20","author":"Howard","year":"2002","journal-title":"J Clin Oncol"},{"issue":"suppl 2","key":"10.3816\/CLM.2002.n.014_bib65","first-page":"57","article-title":"Combined immuno-chemotherapy (RFCM) is superior to a fludarabine-containing chemotherapy (FCM) alone in recurrent follicular and mantle cell lymphoma- results of a prospective randomized comparison of the German Low Grade Lymphoma Study Group","volume":"13","author":"Hiddemann","year":"2002","journal-title":"Ann Oncol"},{"issue":"suppl 2","key":"10.3816\/CLM.2002.n.014_bib66","first-page":"8","article-title":"Mantle cell lymphoma (MCL)- Update on results after R-HCVAD without stem cell transplant (SCT)","volume":"13","author":"Romaguera","year":"2002","journal-title":"Ann Oncol"},{"key":"10.3816\/CLM.2002.n.014_bib67","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/S1083-8791(00)70028-0","article-title":"Immunotherapy with rituximab during peripheral blood stem cell transplantation for non-Hodgkin's lymphoma","volume":"6","author":"Flinn","year":"2000","journal-title":"Biol Blood Marrow Transplant"},{"issue":"suppl 1","key":"10.3816\/CLM.2002.n.014_bib68","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1038\/sj.bmt.1703296","article-title":"Rituximab: enhancing stem cell transplantation in mantle cell lymphoma","volume":"29","author":"Gianni","year":"2002","journal-title":"Bone Marrow Transplant"},{"key":"10.3816\/CLM.2002.n.014_bib69","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1053\/sonc.2002.30143","article-title":"Immunotherapy with rituximab following high-dose therapy and autologous stem-cell transplantation for mantle cell lymphoma","volume":"29","author":"Mangel","year":"2002","journal-title":"Semin Oncol"},{"key":"10.3816\/CLM.2002.n.014_bib70","series-title":"Annual of Lymphoid Medicine","first-page":"153","article-title":"Monoclonal antibodies have finally arrived","author":"Lucas","year":"2001"},{"issue":"suppl EHA-4","key":"10.3816\/CLM.2002.n.014_bib71","first-page":"14","article-title":"Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma patients","volume":"84","author":"Coiffier","year":"1999","journal-title":"Haematologica"},{"key":"10.3816\/CLM.2002.n.014_bib72","first-page":"58","article-title":"Radiolabeled antibody therapy of B-cell lymphomas","volume":"26","author":"Press","year":"1999","journal-title":"Semin Oncol"},{"key":"10.3816\/CLM.2002.n.014_bib73","first-page":"S3281","article-title":"Radioimmunotherapy of relapsed non-Hodgkin's lymphoma with zevalin, a 90Y-labeled anti-CD20 monoclonal antibody","volume":"5","author":"Wiseman","year":"1999","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CLM.2002.n.014_bib74","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1007\/s002590000276","article-title":"Phase I\/II 90Y-Zevalin (yttrium- 90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma","volume":"27","author":"Wiseman","year":"2000","journal-title":"Eur J Nucl Med"},{"key":"10.3816\/CLM.2002.n.014_bib75","doi-asserted-by":"crossref","first-page":"3793","DOI":"10.1200\/JCO.1999.17.12.3793","article-title":"Phase I\/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20+ B-cell non-Hodgkin's lymphoma","volume":"17","author":"Witzig","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2002.n.014_bib76","first-page":"74","article-title":"The use of ibritumomab tiuxetan radioimmunotherapy for patients with relapsed B-cell non-Hodgkin's lymphoma","volume":"27","author":"Witzig","year":"2000","journal-title":"Semin Oncol"},{"key":"10.3816\/CLM.2002.n.014_bib77","first-page":"279a","article-title":"Response to zevalin is superior to response to rituximab regardless of age and extent of disease","volume":"20","author":"Witzig","year":"2001","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.3816\/CLM.2002.n.014_bib78","first-page":"S21","article-title":"Iodine-131 anti-B1 antibody for B-cell lymphoma: an update on the Michigan Phase I experience","volume":"39","author":"Wahl","year":"1998","journal-title":"J Nucl Med"},{"key":"10.3816\/CLM.2002.n.014_bib79","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1200\/JCO.2001.19.19.3918","article-title":"Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas","volume":"19","author":"Kaminski","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2002.n.014_bib80","doi-asserted-by":"crossref","first-page":"3270","DOI":"10.1200\/JCO.1998.16.10.3270","article-title":"Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue","volume":"16","author":"Liu","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2002.n.014_bib81","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1056\/NEJM199310213291702","article-title":"Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support","volume":"329","author":"Press","year":"1993","journal-title":"N Engl J Med"},{"key":"10.3816\/CLM.2002.n.014_bib82","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1200\/JCO.1996.14.7.1974","article-title":"Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma","volume":"14","author":"Kaminski","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2002.n.014_bib83","doi-asserted-by":"crossref","first-page":"2934","DOI":"10.1182\/blood.V96.9.2934","article-title":"A phase I\/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas","volume":"96","author":"Press","year":"2000","journal-title":"Blood"},{"key":"10.3816\/CLM.2002.n.014_bib84","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.1182\/blood.V99.9.3158","article-title":"High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma","volume":"99","author":"Gopal","year":"2002","journal-title":"Blood"},{"key":"10.3816\/CLM.2002.n.014_bib85","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1002\/cncr.10307","article-title":"High-dose myeloablative radioimmunotherapy of mantle cell non-Hodgkin lymphoma with the iodine- 131-labeled chimeric anti-CD20 antibody C2B8 and autologous stem cell support. Results of a pilot study","volume":"94","author":"Behr","year":"2002","journal-title":"Cancer"},{"key":"10.3816\/CLM.2002.n.014_bib86","first-page":"93","article-title":"Mantle cell lymphoma","volume":"84","author":"Hiddemann","year":"1999","journal-title":"Haematologica"},{"issue":"suppl 2","key":"10.3816\/CLM.2002.n.014_bib87","first-page":"9","article-title":"What is new mantle cell lymphoma- myeloblative radiochemotherapy with subsequent autologous blood stem cell transplantation in mantle cell lymphoma","volume":"13","author":"Hiddeman","year":"2002","journal-title":"Ann Oncol"},{"key":"10.3816\/CLM.2002.n.014_bib88","first-page":"2644","article-title":"Combination immunotherapy of relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma with rituximab and interferon-?-2a","volume":"6","author":"Davis","year":"2000","journal-title":"Clin Cancer Res"},{"issue":"suppl 1","key":"10.3816\/CLM.2002.n.014_bib89","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1093\/annonc\/11.suppl_1.S107","article-title":"Treatment of multiple myeloma by antibody mediated immunotherapy and induction of myeloma selective antigens","volume":"11","author":"Treon","year":"2000","journal-title":"Ann Oncol"},{"key":"10.3816\/CLM.2002.n.014_bib90","first-page":"297a","article-title":"Interferon-\u03b3 can augment multiple antigens on the surface of lymphoproliferative disorders that can be targeted using monoclonal antibodies","volume":"99","author":"Venugopal","year":"2000","journal-title":"Blood"},{"key":"10.3816\/CLM.2002.n.014_bib91","first-page":"131a","article-title":"Cytokines enhance rituximabbinding to tumor cells","volume":"96","author":"Venugopal","year":"2000","journal-title":"Blood"},{"key":"10.3816\/CLM.2002.n.014_bib92","first-page":"951","article-title":"Clinical activity and safety of combination immunotherapy with IFN-\u03b3 2a and Rituximab in patients with relapsed low grade non-Hodgkin's lymphoma","volume":"86","author":"Sacchi","year":"2001","journal-title":"Haematologica"},{"key":"10.3816\/CLM.2002.n.014_bib93","series-title":"Cell Cycle Checkpoints","article-title":"Small molecule inhibitors of cyclin-dependent kinases: preclinical and clinical development","author":"Shapiro","year":"2001"},{"key":"10.3816\/CLM.2002.n.014_bib94","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1093\/jnci\/92.5.376","article-title":"Preclinical and clinical development of cyclin- dependent kinase modulators","volume":"92","author":"Senderowicz","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.3816\/CLM.2002.n.014_bib95","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/sj.leu.2401994","article-title":"Development of cyclin-dependent kinase modulators as novel therapeutic approaches for hematological malignancies","volume":"15","author":"Senderowicz","year":"2001","journal-title":"Leukemia"},{"key":"10.3816\/CLM.2002.n.014_bib96","first-page":"2024","article-title":"Apoptosis: target of cancer therapy","volume":"8","author":"Ferreira","year":"2002","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CLM.2002.n.014_bib97","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1200\/JCO.2001.19.7.1985","article-title":"Phase II study of the cyclin-dependent kinase inhibitor flavopiridol administered to patients with advanced gastric carcinoma","volume":"19","author":"Schwartz","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2002.n.014_bib98","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1200\/JCO.2001.19.8.2319","article-title":"Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms","volume":"19","author":"Sausville","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2002.n.014_bib99","first-page":"1590","article-title":"A phase II trial of the cyclin-dependent kinase inhibitor flavopiridol in patients with previously untreated stage IV non-small cell lung cancer","volume":"7","author":"Shapiro","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CLM.2002.n.014_bib100","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1182\/blood.V95.2.619","article-title":"Increased proteasome degradation of cyclin-dependent kinase inhibitor P27 is associated with a decreased overall survival in mantle cell lymphoma","volume":"95","author":"Chiarle","year":"2000","journal-title":"Blood"},{"key":"10.3816\/CLM.2002.n.014_bib101","first-page":"465a","article-title":"Anti-Tumor activity of the proteasome inhibitor PS-341 in mantle cell lymphoma B cells","volume":"98","author":"Pham","year":"2001","journal-title":"Blood"},{"key":"10.3816\/CLM.2002.n.014_bib102","first-page":"2638","article-title":"The proteasome inhibitor PS-341 in cancer therapy","volume":"5","author":"Teicher","year":"1999","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CLM.2002.n.014_bib103","first-page":"2615","article-title":"Proteasome inhibitors: a novel class of potent and effective antitumor agents","volume":"59","author":"Adams","year":"1999","journal-title":"Cancer Res"},{"key":"10.3816\/CLM.2002.n.014_bib104","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1023\/A:1006321828515","article-title":"Proteasome inhibition: a new strategy in cancer treatment","volume":"18","author":"Adams","year":"2000","journal-title":"Invest New Drugs"},{"key":"10.3816\/CLM.2002.n.014_bib105","series-title":"Educational Book - Spring 2000","article-title":"Therapeutic vaccines against hematological malignancies","author":"Kwak","year":"2000"},{"key":"10.3816\/CLM.2002.n.014_bib106","first-page":"312","article-title":"Vaccine strategies in indolent lymphomas","author":"Stevenson","year":"1999","journal-title":"Hematology - American Society of Hematology Education Program Book"},{"key":"10.3816\/CLM.2002.n.014_bib107","first-page":"1555","article-title":"Antibodies elicited by naked DNA vaccination against the complementary-determining region 3 hypervariable region of immunoglobulin heavy chain idiotypic determinants of B-lymphoproliferative disorders specifically react with patients' tumor cells","volume":"61","author":"Rinaldi","year":"2001","journal-title":"Cancer Res"},{"issue":"Suppl EHA-4","key":"10.3816\/CLM.2002.n.014_bib108","first-page":"11","article-title":"DNA vaccines against haematological malignancies","volume":"84","author":"Stevenson","year":"1999","journal-title":"Haematologica"},{"issue":"suppl 2","key":"10.3816\/CLM.2002.n.014_bib109","first-page":"9","article-title":"Phase II study of idiotype vaccine following EPOCH-rituximab treatment in untreated mantle cell lymphoma","volume":"13","author":"Wilson","year":"2002","journal-title":"Ann Oncol"},{"key":"10.3816\/CLM.2002.n.014_bib110","first-page":"772","article-title":"Chromosome 9p abnormalities as targets for chemotherapy","volume":"40","author":"Carson","year":"1999","journal-title":"Proceedings of the 90th Annual Meeting of the American Association for Cancer Research"},{"key":"10.3816\/CLM.2002.n.014_bib111","first-page":"1492","article-title":"Use of alanosine as a methylthioadenosine phosphorylase-selective therapy for T-cell acute lymphoblastic leukemia in vitro","volume":"59","author":"Batova","year":"1999","journal-title":"Cancer Res"}],"container-title":["Clinical Lymphoma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526965511702512?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526965511702512?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T06:09:12Z","timestamp":1588918152000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526965511702512"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,9]]},"references-count":111,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2002,9]]}},"alternative-id":["S1526965511702512"],"URL":"https:\/\/doi.org\/10.3816\/clm.2002.n.014","relation":{},"ISSN":["1526-9655"],"issn-type":[{"value":"1526-9655","type":"print"}],"subject":[],"published":{"date-parts":[[2002,9]]}}}